prostate

Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.

Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer.

Led the proton dose-escalation trial in prostate cancer and the comparative-effectiveness debate over proton therapy.

Created the low, intermediate and high-risk classification that every prostate cancer decision starts from.

AR-V7 is a shortened androgen receptor that lacks the part hormone drugs bind, so it stays active without testosterone. Found in circulating tumour cells, it predicts poor response to abiraterone and enzalutamide, but no label uses it yet.

London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.

Led CHAARTED, which showed adding docetaxel to hormone therapy extends survival in newly metastatic prostate cancer.

Radiation oncologist who built AI models from trial slides to decide which prostate cancer patients need hormone therapy.

British radiation oncologist who led CHHiP, the trial that showed prostate cancer can be treated in 20 radiotherapy sessions rather than 37 with the same results, changing practice worldwide.

Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.

Urologist who led the CCGA study validating the Galleri methylation-based multi-cancer detection test.

Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease.

Led ProtecT, the trial that showed monitoring, surgery and radiotherapy give equally low prostate cancer death rates at 15 years.

London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer.

Led PROMIS, the trial that showed MRI can safely spare a quarter of men from prostate biopsy.

Led TAX 327, which made docetaxel the first life-extending chemotherapy for prostate cancer, and has spent decades pressing for higher trial standards.

Led TITAN and MAGNITUDE, bringing apalutamide to hormone-sensitive disease and niraparib to HRR-mutant prostate cancer.

Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.

Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346.

Urologist behind PROMIS and PRECISION, which put MRI before biopsy in the prostate cancer pathway.

Led ARASENS and SPARTAN, trials that established darolutamide triplet therapy and apalutamide for prostate cancer.

Founder and chair of the APCCC consensus conference that guides advanced prostate cancer management worldwide.

Los Angeles urologist who was lead author of EMBARK, the trial that established enzalutamide for men whose prostate cancer is returning fast after surgery or radiotherapy.